Loading clinical trials...
Loading clinical trials...
Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines. The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hôpital Pasteur 2 - Service d'Ophtalmologie
Nice, France
Start Date
November 26, 2018
Primary Completion Date
January 12, 2021
Completion Date
August 19, 2021
Last Updated
April 18, 2022
100
ACTUAL participants
Aqueous humor samples collection
PROCEDURE
Lead Sponsor
Centre Hospitalier Universitaire de Nice
NCT07249216
NCT06787482
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions